2.9.31. PARTICLE SIZE ANALYSIS BY LASER LIGHT DIFFRACTION
the refractive index values used, since small differences in 312 See the information section on general monographs (cover pages) EUROPEAN PHARMACOPOEIA 6.0 2.9.31.
Download 2.9.31. PARTICLE SIZE ANALYSIS BY LASER LIGHT DIFFRACTION
Information
Domain:
Source:
Link to this page:
Documents from same domain
5.1. GENERAL TEXTS ON MICROBIOLOGY - …
www.uspbpep.comEUROPEAN PHARMACOPOEIA 6.0 5.1.1. Methods of preparation of sterile products 5.1. GENERAL TEXTS ON MICROBIOLOGY 01/2008:50101 …
2.9.3. DISSOLUTION TEST FOR SOLID DOSAGE …
www.uspbpep.com2.9.3. Dissolution test for solid dosage forms EUROPEAN PHARMACOPOEIA 5.0 For the basket apparatus, place the preparation in a …
Insulinum humanum - uspbpep.com
www.uspbpep.comInsulin, human EUROPEAN PHARMACOPOEIA 5.0 01/2005:0838 INSULIN, HUMAN Insulinum humanum C257H383N65O77S6 Mr 5808 DEFINITION Human insulin is a 2-chain peptide having the structure of
2.8.16. DRY RESIDUE OF EXTRACTS - uspbpep.com
www.uspbpep.com2.8.16. Dry residue of extracts EUROPEAN PHARMACOPOEIA 6.0 Starting with solution D prepare the following sequence of dilutions: Solution D (ml) 1.2 1.5 2.0 3.0 6.0 8.0 water R (ml) 8.8 8.5 8.0 7.0 4.0 2.0
2.9.3. DISSOLUTION TEST FOR SOLID DOSAGE …
www.uspbpep.com2.9.3. Dissolution test for solid dosage forms EUROPEAN PHARMACOPOEIA 6.0 A and B dimensions do not vary more than 0.5 mm when part is rotated on center line axis. ...
2.2.2. DEGREE OF COLORATION OF LIQUIDS - …
www.uspbpep.com2.2.2. Degree of coloration of liquids EUROPEAN PHARMACOPOEIA 6.0 made lie in the range of 1750-2000 NTU. Linearity must be demonstrated by constructing a …
2.6.12. MICROBIOLOGICAL EXAMINATION OF …
www.uspbpep.comEUROPEAN PHARMACOPOEIA 6.0 2.6.12. Total viable aerobic count TheMostProbableNumber(MPN)methodisreserved for bacterial counts when no other method is available.
PIRACETAM - uspbpep.com
www.uspbpep.comEUROPEAN PHARMACOPOEIA 5.4 Polysorbate 80 Reference solution (a).Dissolve5mgofthesubstanceto be examined and 10 µl of2-pyrrolidone R in a mixture of 10 volumes of acetonitrile R1 and 90 volumes of water R
2.2.3. POTENTIOMETRIC DETERMINATION OF pH - …
www.uspbpep.com2.2.3. Potentiometric determination of pH EUROPEAN PHARMACOPOEIA 6.0 Table 2.2.2.-5. - Reference solutions GY Volumes in millilitres Reference solution StandardsolutionGY Hydrochloric acid
2.9.20. PARTICULATE CONTAMINATION: VISIBLE …
www.uspbpep.com2.9.20. Particulate contamination: visible particles EUROPEAN PHARMACOPOEIA 6.0 Wet the inside of the filter holder fitted with the membrane filter with several millilitres ofparticle-free water R.Transfer
Related documents
HMPC Guideline on GACP - European Medicines Agency
www.ema.europa.euEuropean Pharmacopoeia 2 The term “herbal preparation” should be considered as equivalent to the term “herbal drug preparation” as defined in the European Pharmacopoeia EMEA 2006 4/11 2.3 Considerations and recommendations in this Guideline are intended for all participants
EUROPEAN PHARMACOPOEIA 6.0 2.2.5. Relative density
uspbpep.comEUROPEAN PHARMACOPOEIA 6.0 2.2.5. Relative density Table 2.2.3.-2. – pH of reference buffer solutions at various temperatures Temperature (°C) Potassium tetraoxalate 0.05 M Potassium hydrogen tartrate saturated at 25 °C Potassium dihydrogen citrate 0.05 M Potassium hydrogen phthalate 0.05 M Potassium dihydrogen phosphate 0.025 M + disodium ...
EMA versus US-FDA regulatory requirements regarding ...
www.dgra.debioequivalence studies in the European Union and the United States of America that need to be fulfilled in order to successfully submit a generic application according to Directive 2001/83/EC [2], Article 10.1, or an Abbreviated New Drug
Safety issues in the preparation of - WHO | World Health ...
www.who.intexample, in 2008, Australia spent 7.3 million US dollars on homeopathic medicines;5 France spent more than 408 million; Germany 346 million and the United Kingdom more than 62 million US dollars.6 In the United States, adults spent 2.9 billion US …
Comirnaty, INN-COVID-19 mRNA Vaccine (nucleoside-modified)
www.ema.europa.euAssessment report EMA/707383/2020 Page 8/140 1. Background information on the procedure 1.1. Submission of the dossier The applicant BioNTech Manufacturing GmbH submitted on 30 November 2020 an application for
COSMETIC INGREDIENT LABELLING IN THE EUROPEAN …
cosmeticseurope.eu7 Labelling Rules 7 1. Order of declaration 7 2. Materials not regarded as ingredients 8 3. Position and legibility of the declaration 8 4. Off-pack labelling - provision for limited pack or label size 9 5. Products sold by mail order 9 6. Multi-product packs 9 7.